SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Yarrow Bioscience Reports Q3 2026 Results, $268.9 Million in Cash

Yarrow Bioscience reported a third-quarter 2026 net loss of $9.7 million, with $268.9 million in cash and cash equivalents as of September 30. The company said its cash is expected to fund operations into 2030. Enrollment is ongoing in the Phase 2a portion of its DIRECTION-GD trial, with topline re…

YARW

Related stories